The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat

DOI: 10.1080/2162402X.2016.1219008

Keywords: Breast cancer, entinostat, exemestane, histone deacetylase inhibitors, HLA-DR, immune checkpoint receptor, immune subsets, monocyte, myeloid-derived suppressor cell, regulatory T cell

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text